Polyclonal T‐cell antibody induction showed no clear difference in mortality compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in acute rejection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in infection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in bronchiolitis obliterans syndrome compared with interleukin‐2 receptor antagonist induction (moderate certainty).
It is very uncertain whether antibody (T cell) + steroid changes graft loss censored for death compared with steroid alone (very low certainty).
Antibody (T cell) + steroid showed no clear difference in death compared with steroid alone (low certainty).
Antibody (T cell) + steroid showed no clear difference in failure of reversal of acute rejection episode compared with steroid alone (low certainty).
Antibody (T cell) + steroid showed no clear difference in recurrent rejection compared with steroid alone (low certainty).
It is very uncertain whether antibody (T cell) + steroid changes graft loss or death with a functioning graft compared with steroid alone (very low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 to 4 anaemia compared with chemotherapy alone (low certainty).
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 hypokalaemia compared with chemotherapy alone (low certainty).
The review found no eligible studies for this question.
Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).